Gastric Bypass Surgery Leads to Long-term Remission or Improvement of Type 2 @entity6 and Significant XXXX .

@entity1 @entity353 @entity6 @entity28 @entity532 @entity164
OBJECTIVES: The aim of the study was to compare long-term outcomes of 2 groups of morbidly @entity28 @entity1 with @entity6 -1 managed by Roux-en-Y gastric bypass surgery and a comparable group managed medically. METHODS: The present study was a single-institution retrospective study. Of the 173 @entity28 @entity1 with @entity6 undergoing gastric bypass surgery between January 2000 and July 2004, 78 @entity1 (45%) were followed for at least 10 years. The control group consisted of 80 @entity6 @entity1 from the same period with similar body mass index, age, race, and severity of @entity6 . The median follow-up was 11 years for both the groups. RESULTS: The group undergoing gastric bypass surgery had greater percentage of excess @entity353 than the control group-66% versus -1.6%, respectively. Forty-one @entity1 (52.6%) in the surgery group had complete remission of @entity6 and 5 (6.4%) had partial remission. Twelve @entity1 (15.4%) had @entity6 recurrence after initial remission. No @entity1 in the control group had remission of @entity6 . Compared with the control group, the group undergoing gastric bypass surgery had a significantly reduced incidence of microvascular complications-46.3% versus 11.5%, and macrovascular complications-20.3% versus 5%, respectively (P<0.01). CONCLUSIONS: In this study, we demonstrated that after 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgical medical management, resulted in significantly greater @entity353 , reduction in hemoglobin A1c, and use of antidiabetic medications, and very importantly a lower incidence of both @entity532 in @entity28 @entity1 with @entity164 2 @entity6 .
